Latest news
Capsule inhaler ICOcap™ from Iconovo CE-marked for clinical trials
Iconovo announce that the capsule-based dry powder inhaler ICOcap™ is CE-marked for use in clinical trials
ICOcap™ is now available for customers…
Market analysis of Iconovo by Danske Bank
Stepping closer to important milestones
Iconovo’s Q1 results were confirmatory for us. Since mid-April, Iconovo has had a new CEO, Johan Wäborg, with…
Possessing a unique combination
of engineering and pharma expertise, Iconovo can provide the optimal combination of customized inhalers and tailored formulations.
ICONOVO AB
VISITING ADDRESS
Ideon, Delta 6 Lund
Ideongatan 3B
POSTAL ADDRESS
Iconovo AB
Ideongatan 3A-B
SE-223 62 LUND
Sweden
CONTACT
Phone: +46 46 275 67 77
Director Business Development and Alliances
Måns Österberg
Mail: mans.osterberg@iconovo.se
CEO
Anders Månsson
Mail: anders.mansson@iconovo.se